MedTrace Logo

Frequency and Predictors of Post-ERCP Pancreatitis in a South Asian Tertiary Care Center

NCT07125014 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-08-15

No results posted yet for this study

Summary

This study was conducted at the Department of Gastroenterology, Lady Reading Hospital, Peshawar, Pakistan, from January 2023 to December 2023. It aimed to determine how often patients develop pancreatitis (inflammation of the pancreas) after undergoing a procedure called endoscopic retrograde cholangiopancreatography (ERCP), and to identify the main factors that increase this risk. We reviewed the medical records of 300 adult patients who had ERCP for various conditions, such as bile duct stones, tumors, and strictures. We assessed patient characteristics, procedure details, and laboratory results to see which factors were linked to post-ERCP pancreatitis. The study found that prolonged cannulation time, injection of contrast into the pancreatic duct, and high levels of C-reactive protein before the procedure were the strongest predictors of this complication. These findings may help doctors identify high-risk patients and take preventive steps to reduce the chances of pancreatitis after ERCP.

Conditions

  • Post-ERCP Pancreatitis

Interventions

PROCEDURE

Observational study

This is an observational study with no experimental or therapeutic interventions administered to participants. All data were collected retrospectively from existing hospital records for patients who underwent ERCP between January 2023 and December 2023 at Lady Reading Hospital, Peshawar. No drugs, devices, or procedures were assigned to participants as part of this research.

Sponsors & Collaborators

  • Nangarhar University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-12-14
Completion
2023-12-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07125014 on ClinicalTrials.gov